Abstracts Archive - Page 790 of 1683 - ATC Abstracts

2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
N. Wilson, N. Sulejmani, A. Jantz, A. Patel, B. Summers.
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…
2018 American Transplant Congress
Using Machine Learning and Simulation to Compare High Risk Kidney Transplant Survival to Waiting for a Non High Risk Organ
E. Mark, D. Goldsman, P. Keskinocak, B. Gurbaxani.
H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA.
The purpose of this study is to help patients decide whether to accept a kidney from a donor with a potential disease. We consider infectious…
2018 American Transplant Congress
Recovery of Wild-Type Genotype after Documented Ganciclovir-Resistance in Transplant Recipients with Recurrent CMV Viremia
J. Fose, M. Jorgenson, Z. Degrave, R. Redfield, J. Smith, D. Mandelbrot.
University of Wisconsin Hospital, Madison; University of Wisconsin School of Medicine and Public Health, Madison.
Purpose: Ganciclovir-resistant cytomegalovirus (GR-CMV) is serious complication after transplantation. Recurrence after primary GR-CMV infection is common, with literature defined rates of approximately 20-30%. It is…
2018 American Transplant Congress
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients
I. Helanterä,¹ F. Ortiz,² R. Loginov,³ L. Mannonen,³ M. Lempinen,¹ I. Lautenschlager.³
¹Transplantation and Liver Surgery, Helsinki University Hospital, Helsinki, Finland; ²Nephrology, Helsinki University Hospital, Helsinki, Finland; ³Virology, Helsinki University Hospital, Helsinki, Finland.
A. Prophylaxis has mostly replaced preemptive therapy in CMV seronegative recipients of kidneys from seropositive donors (D+/R-). Primary infections occur commonly even after six months…
2018 American Transplant Congress
Cause of ESRD is Not Associated with Risk of Post-Transplant CMV Infection
S. Panzer, S. Peery, B. Astor, A. Djamali, T. Singh.
University of Wisconsin Madison, Madison, WI.
Purpose: Cytomegalovirus (CMV) infection is commonly encountered following kidney transplantation and is associated with patient morbidity and mortality. While preventative pharmacotherapy is used to prevent…
2018 American Transplant Congress
Outpatient Prophylactic Valganciclovir Dose Optimization Post-Renal Transplant
M. Spinner,¹ V. Athans,¹ C. Koval.²
¹Dept. of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Dept. of Infectious Diseases, Cleveland Clinic, Cleveland, OH.
Purpose: Renal function rapidly changes post-transplant requiring dose adjustment of CMV prophylaxis. We describe valganciclovir (VGCV) dosing accuracy in the outpatient setting and its associated…
2018 American Transplant Congress
Relation between Seroprevalence of Cytomegalovirus and Graft Survival in Japanese Kidney Transplant Recipients: The Japan Academic Consortium of Kidney Transplantation Study
K. Miyake,^1,2 M. Okumi,¹ K. Unagami,³ Y. Kakuta,¹ H. Shirakawa,⁴ K. Omoto,⁵ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Kidney Transplantation, Shonan Kamakura General Hospital, Kamakura, Japan; ³Nephrology, Tokyo Women's Medical University, Tokyo, Japan; ⁴Urology, Okubo Hospital, Tokyo, Japan; ⁵Urology, Toda Chuo General Hospital, Saitama, Japan.
BackgroundCytomegalovirus (CMV) infection is one of major causes of morbidity in kidney transplant recipients (KTRs). However, the current prevalence of CMV in KTRs and the…
2018 American Transplant Congress
Long-Term Outcome of Kidney Transplant Recipient with HTLV-1 Infection
N. Goto,¹ M. Minami,¹ K. Futamura,² M. Okada,¹ M. Tsujita,¹ T. Hiramitsu,² S. Narumi,² Y. Watarai.²
¹Nagoya Daini Red Cross Hospital, Transplant Nephrology, Nagoya, Japan; ²Nagoya Daini Red Cross Hospital, Transplant Surgery, Nagoya, Japan.
BackgroundThe human T-lymphotropic virus (HTLV-I), which is endemic in southern Japan, is recognized as the cause of adult T cell leukemia-lymphoma (ATL) and HTLV-1-associated myelopathy…
2018 American Transplant Congress
Brincidofovir for Disseminated Adenovirus in Kidney and Kidney-Pancreas Transplant Recipients: Report of a Case Series
L. Bowman, R. Baliga, C. Mayer.
Tampa General Hospital, Tampa, FL; Florida Kidney Physicians, Tampa, FL; Infectious Disease Associates of Tampa Bay, Tampa, FL.
Background: Adenoviruses (AdV) are DNA viruses that can cause significant morbidity and mortality rates up to 50% with disseminated disease. The incidence post-renal transplantation is…
2018 American Transplant Congress
Effect of Influenza Vaccine in Patients with Kidney Transplant
K. Tsujimura,¹ M. Ota,¹ H. Ishida,² K. Tanabe.²
¹Surgery, Tomishiro Central Hospital, Tomishiro-shi, Okinawa, Japan; ²Urology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
Objective: In this study, we aimed to evaluate the effect of influenza vaccine in kidney transplant recipients.Methods: We retrospectively studied 98 participants who underwent kidney…